This clinical trial is focused on evaluating the effectiveness and safety of a new contrast agent called gadoquatrane for use in MRI scans. The study is specifically looking at adults who have known or suspected issues with their brain or spinal cord, which are part of the central nervous system. The trial will compare gadoquatrane to other approved contrast agents that are already used in medical practice, such as gadoteric acid, gadobutrol, and gadoteridol. These agents help improve the clarity of MRI images, making it easier for doctors to see and diagnose problems.

The purpose of the study is to determine if gadoquatrane is as effective as the existing contrast agents. Participants in the study will undergo two MRI scans: one using gadoquatrane and another using one of the other approved contrast agents. The study is designed to be double-blind, meaning neither the participants nor the researchers will know which contrast agent is being used during each scan. This helps ensure that the results are unbiased and reliable.

Throughout the study, researchers will assess various aspects of the MRI images, such as how well the contrast agent highlights different areas and how clearly it defines the structures within the brain or spinal cord. The study will also monitor any side effects or adverse reactions to the contrast agents. The goal is to provide valuable information about the potential benefits and risks of using gadoquatrane in MRI scans for diagnosing central nervous system conditions.